Drugs /

tt-00420

Back to Drugs List

Overview

NCI Definition [1]:
An orally available small molecule inhibitor of Aurora kinases (AKs) A and B and other currently undisclosed kinases with potential antineoplastic and immunomodulatory activities. Upon oral administration, Aurora kinase inhibitor TT-00420 selectively binds to and inhibits AKs A and B, which may inhibit cell division in tumor cells that overexpress AKs. TT-00420 may also target other not yet disclosed kinases that play a role in tumor-associated inflammation and immune evasion. Aurora kinases are serine-threonine kinases that play essential roles in mitotic checkpoint control and are overexpressed by a wide variety of cancer cell types.

Clinical Trials

View Clinical Trials for tt-00420

Tt-00420 has been investigated in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials investigating tt-00420, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open).

ER Negative, ER No Expression, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for tt-00420 clinical trials.

Breast carcinoma and malignant solid tumor are the most common diseases being investigated in tt-00420 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Tt-00420
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating tt-00420 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
multi-kinase inhibitor tt-00420, ak a/b inhibitor tt-00420, tt 00420, tt00420, aurora kinase a/b inhibitor tt-00420
Drug Categories [2]:
Serine/threonine kinase inhibitors
Drug Target(s) [2]:
AURKA, AURKB
NCIT ID [1]:
C162532

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.